TWD 120.0
(0.42%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 394.52 Million TWD | 1446.03% |
2022 | -29.31 Million TWD | 51.83% |
2021 | -60.85 Million TWD | 56.51% |
2020 | -139.92 Million TWD | -136.79% |
2019 | -59.09 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 9.1 Million TWD | -46.49% |
2024 Q1 | 18.68 Million TWD | -95.52% |
2023 Q4 | 416.83 Million TWD | 21178.0% |
2023 FY | - TWD | 1446.03% |
2023 Q2 | -7.84 Million TWD | 52.26% |
2023 Q1 | -16.43 Million TWD | -2153.88% |
2023 Q3 | 1.95 Million TWD | 124.97% |
2022 Q4 | 800 Thousand TWD | 0.0% |
2022 FY | - TWD | 51.83% |
2021 FY | - TWD | 56.51% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | -92.644% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | -70.718% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 561.422% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 74.119% |
Synmosa Biopharma Corporation | 1 Billion TWD | 60.89% |
Orient EuroPharma Co., Ltd. | 582.93 Million TWD | 32.322% |
Center Laboratories, Inc. | -175.17 Million TWD | 325.221% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -1170.678% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -128.847% |
InnoPharmax Inc. | -62.12 Million TWD | 735.093% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -211.435% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 1443.321% |
DV Biomed Co., Ltd. | 407.64 Million TWD | 3.219% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 143.251% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 50.856% |
UniPharma Co., Ltd. | -16.25 Million TWD | 2527.218% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -200.449% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | -72.789% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 1110.709% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -3151.092% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -297.101% |